SavedAdd your journal

Journals / Türkiye Çocuk Hastalıkları Dergisi / 2009 / Cilt: 3 - Sayı: 3

INHALED OR SYSTEMIC STEROID USE FOR PREVENTIVE AND MANAGEMENT PURPOSES IN BRONCHOPULMONARY DYSPLASIA: A CURRENT REVIEW

Bronkopulmoner Displazide Önleyici Ve Tedavi Amaçlı İnhale Veya Sistemik Steroid Kullanımı: Güncel Bir Derleme

S. Ümit SARICI
Ömer ERDEVE
Pages
59–63
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, it is aimed to review the systemic and inhalated steroids used in bronchopulmonary dysplasia and discuss the consensus in this subject

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Inflammation related to mechanical ventilation induced baro and/or volume trauma, oxygen toxicity, infection, decreased surfactant production and increased pulmonary blood flow is accused for bronchopulmonary dysplasia pathogenesis.
📊
Key Findings & Data:Systemic or inhalated steroids are used to stop the inflammatory process.
💡
Conclusion & Impact:Herein, it is aimed to review the systemic and inhalated steroids used in bronchopulmonary dysplasia and discuss the consensus in this subject
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Bronkopulmoner displazi · prematürite · steroid

Abstract

Inflammation related to mechanical ventilation induced baro and/or volume trauma, oxygen toxicity, infection, decreased surfactant production and increased pulmonary blood flow is accused for bronchopulmonary dysplasia pathogenesis. Systemic or inhalated steroids are used to stop the inflammatory process. Herein, it is aimed to review the systemic and inhalated steroids used in bronchopulmonary dysplasia and discuss the consensus in this subject

Özet

Bronkopulmoner displazi patogenezinde mekanik ventilasyon kaynaklı basınç ve/veya hacim travması, oksijen toksisitesi, enfeksiyon, azalmış surfaktan üretimi ve artmış akciğer kan akımı ile ilişkilendirilen inflamasyon suçlanır. İnflamasyon sürecinin durdurulması amaçlı sistemik ve inhale steroidler kullanılmaktadır. Bu yazıda, bronkopulmoner displazi tedavisinde kullanılan sistemik ve inhale steroidlerin gözden geçirilmesi ve bu konuda varılan görüş birliğinin tartışılması amaçlanmıştır.

🔖

Cite This Article

SARICI, S. Ü., ERDEVE, Ö. (2022). INHALED OR SYSTEMIC STEROID USE FOR PREVENTIVE AND MANAGEMENT PURPOSES IN BRONCHOPULMONARY DYSPLASIA: A CURRENT REVIEW. Türkiye Çocuk Hastalıkları Dergisi, Cilt: 3 - Sayı: 3, 59–63. https://ajindex.com/articles/627754

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bhandari A, Schramm CM, Kimble C, Pappagallo M, Hussain N. Effect of a short course of prednisolone in infants with oxygen dependent bronchopulmonary dysplasia. Pediatrics 2008;121:344 Bancalari E. Changes in the pathogenesis and prevention of chro- nic lung disease of prematurity. Am J Perinatol 2001;18:1–9.
  2. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee Sk, Ohlsson A. Changes in the use of postnatal steroids for BPD in 3 large neonatal networks. Pediatrics 2006;118:1328-1335.
  3. Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortiso- ne: study rather than treat. Pediatrics 2006;118:2540-2542.
  4. Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed 2007;92:334-337.
  5. Thebaud B, Watterberg K. Postnatal glucocorticoids in very preterm infants: “The good, the bad, and the ugly”? Pediatrics;107;413-415.
  6. Jones BO, Davies MW. Total steroid dose given to ventilated new- born infants with chronic lung disease. J Paediatr Child Health;43:40-43.
  7. Cole CH, Colton T, Shah B, Abbasi S, MacKinnon BL, Demisse S, Frantz ID 3rd. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005 Zimmerman JJ, Gabbert D, Shivpuri C, Kayata S, Miller J, Ciesi- elski W. Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med;1:140-145.
  8. Cummings JJ, D’Eugionio DB, Gross SJ. A controlled trial of de- xamethasone in preterm infants at high risk of bronchopulmo- nary dysplasia. N Engl J Med 1989;320:1505-1510.
  9. American Academy of Pediatrics, Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-338. Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. J Paediatr Child Health 2002;7:20-28. Barrington KJ. The adverse neuro-developmental effects of post- natal steroids in the preterm infant: a systemic review of RCTs. BCM Pediatrics 2001;1:1. Yeh TF, Lin YJ, Lin HC,Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304 Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics;119:265-272.
  10. Halliday HL, Ehrenkranz RA, Doyle LW. Ear